Learn More
The PI3K/AKT/mTOR pathway has been shown to play an important role in cancer. Starting with compounds 1 and 2 (GDC-0941) as templates, (thienopyrimidin-2-yl)aminopyrimidines were discovered as potent(More)
The discovery of 2 (GDC-0980), a class I PI3K and mTOR kinase inhibitor for oncology indications, is described. mTOR inhibition was added to the class I PI3K inhibitor 1 (GDC-0941) scaffold primarily(More)
Acknowledgments We thank M. Black, D. Kaufman, and the UCLA Gene Imaging Consortium for helpful discussions, and A. Green, K. Nguyen, E. Bauer, D. MacLaren, X. Sun, G. Castanedo, V. Dominguez, J.(More)